Eli Lilly and Company (NYSE: LLY) has once again redefined the pharmaceutical landscape, reporting a “blockbuster” fourth quarter for 2025 that far exceeded Wall Street’s projections. Driven by the explosive demand for its GLP-1 treatments, Mounjaro and Zepbound, the company posted a staggering 43% revenue growth and provided a bullish outlook for 2026 that sent its stock surging past the $1 trillion market cap milestone once again.
Q4 2025 Financial Performance: By the Numbers
Lilly’s financial health reached new heights in the final quarter of 2025, characterized by volume-driven growth and expanding profit margins.
- Total Revenue: $19.3 billion (43% increase YoY), beating the consensus estimate of $17.87 billion.
- Non-GAAP Earnings Per Share (EPS): $7.54 (42% increase YoY), significantly outperforming the expected $6.99.
- Reported Net Income: $6.6 billion, up 50% from $4.4 billion in Q4 2024.
- Gross Margin: 82.5%, a slight expansion driven by favorable product mix and manufacturing efficiencies.
The GLP-1 Duopoly: Lilly Pulls Ahead of Novo Nordisk
The “weight-loss drug race” saw a definitive shift this quarter. While competitor Novo Nordisk issued a cautious 2026 forecast that led to a sharp stock decline, Eli Lilly signaled aggressive expansion.
Mounjaro (Diabetes): Global sales reached $7.41 billion, a 110% increase year-over-year. International adoption was particularly strong, with sales outside the U.S. jumping to $3.3 billion as the drug launched in new Latin American and Asian markets.
Zepbound (Obesity): Revenue for the obesity-specific treatment soared 123% to $4.26 billion. Combined, Mounjaro and Zepbound generated $11.7 billion in quarterly revenue, securing Lilly a dominant 60.5% share of the U.S. incretin market.
2025 was a pivotal year for Lilly,
We reached millions more patients and expanded our manufacturing capacity. Entering our 150th year with a deep pipeline and platforms like LillyDirect, we are positioned to reach more patients than ever and expand our global health impact.
David A. Ricks
Bullish 2026 Guidance: Aiming for $80 Billion+
Defying concerns about pricing pressure from the U.S. government, Lilly issued 2026 guidance that “stunned” analysts. The company expects:
- 2026 Revenue: $80 billion to $83 billion (surpassing the $77.6 billion market consensus).
- 2026 Non-GAAP EPS: $33.50 to $35.00.
Lilly CEO David Ricks highlighted that while global pricing may decline by low-to-mid teens due to new agreements with the U.S. government (including the TrumpRx initiative and expanded Medicare access), the sheer volume of new patients will more than offset the lower per-unit price.
Pipeline and Strategic Milestones
Beyond its current blockbusters, Lilly is preparing for the next generation of metabolic health:
- Orforglipron: The company has submitted its highly anticipated oral GLP-1 pill for regulatory approval in the U.S., Japan, and the EU.
- Manufacturing Expansion: Lilly announced new multi-billion dollar manufacturing facilities in Pennsylvania, Alabama, and Europe to solve the supply-chain bottlenecks that have historically constrained GLP-1 availability.
- Alzheimer’s Progress: Kisunla saw its revenue rise to $109 million in Q4 as it continues to gain market share following its European approval in late 2024.
Novartis Immunology Data at AAD 2026: Rhapsido and Cosentyx Results
Novartis unveils over 20 abstracts at AAD 2026, highlighting Rhapsido’s (remibrutinib) early intervention in CSU and Cosentyx’s (secukinumab) sustained performance in complex skin diseases. […]
Investor Summary
The market’s reaction was swift, with LLY shares jumping by more than 9% in Wednesday’s trading. Analysts point to Lilly’s ability to maintain high margins (projecting a 46%–47.5% performance margin for 2026) and its clear path toward dominating the obesity market through both injectable and oral therapies.
| Metric | Q4 2025 Actual | Wall Street Estimate |
| Revenue | $19.30 Billion | $17.87 Billion |
| Adjusted EPS | $7.54 | $6.99 |
| Mounjaro Sales | $7.41 Billion | $6.65 Billion |
| Zepbound Sales | $4.26 Billion | $3.87 Billion |
